Bristol-Myers Squibb Co. (BMY) said its experimental hepatitis C compounds, protease inhibitor asunaprevir combined with its NS5A inhibitor daclatasvir, cured 77 percent of difficult-to-treat patients 24 weeks after treatment ended, according to a mid-stage study.
Difficult-to-treat patients included those who didn’t respond to prior therapy and patients who were medically ineligible or intolerant to previous treatment, the company said in a statement today.
In a separate mid-stage study, Bristol-Myers’ experimental peginterferon lambda drug had a cure rate similar to peginterferon alfa with fewer side effects, the company said.
To contact the reporter on this story: Makiko Kitamura in London at email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org